Skip to Main content Skip to Navigation
Journal articles

Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group.

Abstract : BACKGROUND: Knowledge about tumour gene mutation status is essential for the treatment of increasing numbers of cancer patients, and testing quality has a major impact on treatment response and cost. In 2012, 4,629 tests for BRAF p.V600 were performed in France, in patients with melanomas. METHODS: Two batches of unstained melanoma sections were sent, in May and November 2012, to the 46 laboratories supported by the French National Institute of Cancer (INCa). An external quality assessment (EQA) evaluated mutation status, response times and compliance with INCa recommendations. RESULTS: All the French laboratories involved in testing participated in the EQA. Fourteen different methods were used to detect BRAF mutations, most consisting of combinations of in-house techniques. False responses were noted in 25/520 cases (4.8%), 11 of which concerned confusion between p.V600E and p.V600K. Thus, 2.7% of responses would have led to inappropriate treatment. Within six months, mean response times decreased from 22 to 12 days (P<0.001), and the percentage of samples evaluated by a pathologist for tumour cell content increased, from 75.2% to 96.9% (P<0.001). CONCLUSION: Despite the use of non-certified methods, the false response rate was low. Nationwide EQA can improve the quality of molecular pathology tests on tumours.
Document type :
Journal articles
Complete list of metadatas

Cited literature [17 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00873750
Contributor : Ed. Bmc <>
Submitted on : Wednesday, October 16, 2013 - 1:07:58 PM
Last modification on : Tuesday, November 17, 2020 - 1:58:03 PM
Long-term archiving on: : Friday, January 17, 2014 - 4:39:49 AM

Identifiers

Citation

Jean-François Emile, Julie Tisserand, Loic Bergougnoux, Frédérique Nowak, Gladwys Faucher, et al.. Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group.. BMC Cancer, BioMed Central, 2013, 13 (1), pp.472. ⟨10.1186/1471-2407-13-472⟩. ⟨inserm-00873750⟩

Share

Metrics

Record views

798

Files downloads

1462